Vision Plus Capital

Vision Plus Capital is a Hangzhou-based venture firm founded by Alibaba veterans, with a thesis built around bringing operational expertise and global networks to early-stage Chinese digital and health technology startups. The firm’s identity is shaped by its founders’ backgrounds inside Alibaba, which gives it pattern recognition for platform businesses and ecosystem-style commercial models.

The healthcare thesis spans digital health, health IT and healthcare software, and AI and machine learning applied to healthcare. Vision Plus Capital invests where AI-enabled platforms are reshaping consumer healthcare experiences, clinical workflows, and the broader digital health ecosystem in China. The Alibaba operational heritage suggests preference for companies with platform potential rather than narrow point solutions.

The firm writes $1M to $5M checks across Seed, Series A, and Series B, which is broader stage coverage than most early-stage Chinese venture funds and reflects a preference for accompanying companies through multiple rounds rather than indexing on a single entry stage. Geographic focus is China with global network reach, and portfolio companies often benefit from connections into Alibaba’s broader ecosystem and international commercial networks.

The team’s defining characteristic is its Alibaba operating background, which translates into hands-on support around platform strategy, e-commerce integration, and ecosystem partnerships. Specific partner names are not provided in the source data, and founders should engage through Vision Plus Capital’s English-language website.

The approach is operationally engaged with a platform mindset. Vision Plus Capital expects founders to think in ecosystem terms and to build companies that can leverage platform dynamics rather than relying on linear sales motions. The firm is a strong fit for Chinese digital health and AI healthcare founders building platform businesses who value Alibaba-flavored operating expertise. Founders building narrow vertical software without platform potential or operating outside the Chinese commercial context will find less alignment.